|
|
|
|
|
|
Sponsors and Collaborators: |
Beth Israel Deaconess Medical Center Sanofi-Aventis |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00585078 |
The purpose of this study is to determine the effectiveness and safety of the drugs capecitabine and oxaliplatin in patients who have been diagnosed with pancreatic cancer.
Condition | Intervention | Phase |
Pancreatic Cancer |
Drug: Capecitabine Drug: Oxaliplatin |
Phase II |
MedlinePlus related topics: | Cancer Pancreatic Cancer |
Drug Information available for: | Capecitabine Oxaliplatin |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma |
Estimated Enrollment: | 37 |
Study Start Date: | April 2004 |
Estimated Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sanjay Jain, MD | 6170667-9236 |
United States, Massachusetts | |||||
Beth Israel Deaconess Medical Center | Recruiting | ||||
Boston, Massachusetts, United States, 02115 |
Beth Israel Deaconess Medical Center |
Sanofi-Aventis |
Principal Investigator: | Sanjay Jain, MD | Beth Israel Deaconess Medical Center |
Responsible Party: | Beth Israel Deaconess Medical Center ( Sanjay Jain, MD ) |
Study ID Numbers: | 03-398, OX-03-033 |
First Received: | December 24, 2007 |
Last Updated: | December 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00585078 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|